Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 21 - 30 of about 184   

Articles published

GSK 1,553.50 -10.00 (-0.64%)
price chart
Brand Face-Off: GlaxoSmithKline plc (ADR) vs. Merck & Co., Inc.
Pharmaceutical giants GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK) have charted different paths during the last year.
Related articles »  
FDA approves injectable diabetes drug from Glaxo
April 15. The Associated Press. WASHINGTON - The Food and Drug Administration said Tuesday it approved a new injectable drug from GlaxoSmithKline plc for adults with Type 2 diabetes. More News. Read more Dollars & Sense. The agency cleared the ...
US approves injectable diabetes drug from GlaxoSmithKline  Economic Times
GSK receives US approval for once-weekly type 2 diabetes treatment, Tanzeum ...  Wall Street Journal
Related articles »  
Healthcare Recent Insider Buying: Opko Health (NYSE:OPK), GlaxoSmithKline ...
Glaxosmithkline PLC (ADR) (NYSE:GSK) on Thursday said senior executives, including Chief Executive Andrew Witty and Chief Financial Officer Simon Dingermans, acquired shares under the company share reward plan at a price of 1572.79 pence ...
Related articles »  
GlaxoSmithKline plc (ADR) (NYSE:GSK): Markets Take Note of the Pharma ...
Dallas, Texas 03/27/2014 (ustradevoice) - GlaxoSmithKline plc (ADR) (NYSE:GSK) has become a hot pick in the current day market.
Related articles »  
GlaxoSmithKline Breaks Below 200-Day Moving Average - Notable for GSK
In trading on Friday, shares of GlaxoSmithKline plc (Symbol: GSK) crossed below their 200 day moving average of $52.36, changing hands as low as $52.10 per share.
Related articles »  
GlaxoSmithKline plc's Hold Rating Reaffirmed at Jefferies Group (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �hold� rating reiterated by stock analysts at Jefferies Group in a report issued on Monday, American Banking and Market News reports.
Related articles »  
Panmure Gordon Reiterates �Hold� Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK)'s stock had its �hold� rating reaffirmed by research analysts at Panmure Gordon in a report released on Wednesday, Analyst Ratings Network.
GlaxoSmithKline plc Receives �Neutral� Rating from UBS AG (GSK)  Ticker Report
Deutsche Bank Reiterates Hold Rating for GlaxoSmithKline plc (GSK)  Mideast Time
Related articles »  
Why GlaxoSmithKline PLC Shrugged Off Alli's Recall
GlaxoSmithKline (NYSE: GSK ) announced a voluntary recall in the United States and Puerto Rico of its over-the-counter, or OTC, fat-blocking pill Alli last Thursday, after consumers in seven states reported that they had bought bottles containing pills ...
Related articles »  
Sign in or Register
GlaxoSmithKline Plc. (NYSE:GSK) on Wednesday declared its decision to halt the MAGRIT trial, a Phase III trial of its MAGE-A3ii cancer immunotherapeuticiii in non-small cell lung cancer or NSCLC patients, after confirming that it would not be possible ...
Related articles »  
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation ...
Morning Movers in Biotech: Clovis Oncology, Inc., Exact Sciences Corporation, GlaxoSmithKline PLC, and Mylan, Inc. By George Budwell | More Articles March 27, 2014 | Comments (1).
Related articles »